The effects of antiandrogenic medication on relapse rates of sex offenders: A review;Antiandrogene Medikation zur Senkung der Rückfälligkeit von Sexualstraftätern: Ein kritischer Überblick

Recht und Psychiatrie

Volumn 25, Issue 3, 2007, Pages 103-111

  Eher, Reinhard ^a,b   Gnoth, Annika ^b   Birklbauer, Alois ^a   Pfäfflin, Friedemann ^b  

^a UNIVERSITY OF ULM   (Germany)

^b Johannes Kepler Universität Linz ^*  (Austria)

Author keywords

Cyproterone acetate; LH RH agonist; Medroxyprogesterone acetate; Relapse rates; Sex offence

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE; PLACEBO;

EVIDENCE BASED MEDICINE; EXHIBITIONISM; FETISHISM; HUMAN; METHODOLOGY; PATIENT COMPLIANCE; PEDOPHILIA; RECURRENCE RISK; REVIEW; SEXUAL BEHAVIOR; SEXUAL CRIME; SEXUAL DEVIATION; SEXUAL DYSFUNCTION; TRANSVESTISM; UNSPECIFIED SIDE EFFECT;

EID: 34548638647     PISSN: 07242247     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. ABRACEN J, LOOMAN J (2006) Evaluation of civil commitment criteria in a high risk sample of sexual offenders. Journal of Sexual Offender Civil Commitment: Science and the Law, 1, 124-140
2. ALLOLIO B, KEFFEL D, DEUß U, WINKELMANN W (1985) Behandlung sexueller Verhaltensstörungen mit LH-RH-Superagonisten. Deutsche Medizinische Wochenschrift 110 (50), 1952
3. BARBAREE HE, PEACOCK EJ, CORTONI F, MARSHALL WL, SETO M (1998) Ontario Penitentiaries' program. In MARSHALL WL, FERNANDEZ YM, HUDSON SM, WARD T (Eds.), Sourcebook of treatment programs for sexual offenders (pp. 59-77). New York: Plenum
4. BARTOSH DL, GARBY T, LEWIS D, GARY S (2003) Differences in the predictive validity of actuarial risk assessments in relation to sex offender type. International Journal of Offender Therapy and Comparative Criminology, 47, 422-438
5. BIRKLBAUER A, HIRTENLEHNER H (2005) Bewährung nach bedingter Entlassung aus dem Strafvollzug. Österreichische Juristen Zeitung, 55, 938-948
6. BRADFORD JM, PAWLAK A (1993) Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior, 22, 629-641
7. BRIKEN P, NIKA E, BERNER W (2001) Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. Journal Sexual and Marital Therapy, 27, 45-55
8. BRIKEN P, HILL A, BERNER W (2003) Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: A systematic review. Journal of Clinical Psychiatry, 64, 890-897
9. COOPER AJ (1981) A placebo-controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry, 22, 458-465
10. COOPER AJ, CERNOVSKY ZZ (1994) Comparison of cyproterone acetate (CPA) and leuprolide acetate (LHRH agonist) in a chronic pedophile: A clinical case study. Biological Psychiatry, 36, 269-271
11. COOPER AJ, SANDHU S, LOSZTYN S, CERNOVSKY Z (1992) A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles. Canadian Journal of Psychiatry, 37, 687-693
12. CZERNY JP, BRIKEN P, BERNER W (2002) Antihormonal treatment of paraphilic patients in German forensic psychiatric clinics. European Psychiatry, 17, 104-106
13. DAHLE KP (2005a) Psychologische Kriminalprognose. Herbolzheim: Centaurus
14. DAHLE KP (2005b) Chronische Rückfalldelinquenz im Indiviuellen Menschlichen Entwicklungsverlauf: Die Berliner CRIME-Studie. In Psychologische Kriminalprognose (S. 83-196). Herbolzheim: Centaurus
15. DICKEY R (1992) The management of a case of treatment-resistant paraphilia with a long-acting LHRH agonist. Canadian Journal of Psychiatry, 37, 567-569
16. FEDOROFF JP, WISNER-CARLSON R, DEAN S, BERLIN FS (1992) Medroxy-progesterone acetate in the treatment of paraphilic sexual disorders. Rate of relapse in paraphilic men treated in long-term group psychotherapy with or without medroxy-progesterone acetate. Journal of Offender Rehabilitation 18 (3), 109-123
17. FOREL A (1905) Die sexuelle Frage. München: Ernst Reinhardt
18. GRASSWICK LJ, BRADFORD JM (2003) Osteoporosis associated with the treatment of paraphilias: A clinical review of seven case reports. Journal of Forensic Sciences, 48, 849-855
19. GREENBERG D, BRADFORD J, FIRESTONE P, CURRY S (2000) Recidivism of child molesters: A study of victim relationship with the perpetrator. Child Abuse & Neglect, 24, 1485-1494
20. HANSEN H, LYKKE-OLESEN L (1997) Treatment of dangerous sexual offenders in Denmark. The Journal for Forensic Psychiatry, 8, 195-199
21. HANSON RK, BUSSIERE MT (1998) Predicting relapse: A meta-analysis of sexual offender recidivism studies. Journal of Consulting and Clinical Psychology, 66, 348-362
22. HANSON RK, GORDON A, HARRIS AJ, MARQUES JK, MURPHY W, QUINSEY VL, SETO MC (2002) First report of the collaborative outcome data project on the effectiveness of psychological treatment for sex offenders. Sexual Abuse, 14, 169-194
23. HANSON RK, MORTON KE, HARRIS AJ (2003) Sexual offender recidivism risk: What we know and what we need to know. Annals of the New York Academy of Sciences, 989, 154-166
24. HANSON RK, THORNTON D (2001) Static 99: Improving actuarial risk assessments for sex offenders. Ottawa: Public Works and Government Services Canada
25. HARRIS GT, RICE ME, QUINSEY VL, LALUMIERE ML, BOER D, LANG C (2003) A multisite comparison of actuarial risk instruments for sex offenders. Psychological Assessment 15 (3), 413-425
26. HILL A, BRIKEN P, BERNER W (2006) Pharmakotherapie bei Antisozialität und sexueller Gewalt. Neurotransmitter, Sonderheft 2, 41-48
27. HILL A, BRIKEN P, LIETZ K, BERNER W (2005) Standards der Diagnostik, Behandlung und Prognose von Sexual-straftätern. In SCHLÄFKE D, HÄßLER F, FEGERT JM (Hg), Sexualstraftaten (S. 77-98). Stuttgart: Schattauer
28. KRUEGER RB, KAPLAN MS (2001) Depot-leuprolide acetate for treatment of paraphilias: A report of twelve cases. Archives of Sexual Behavior, 30, 409-422
29. LASCHET U (1990) Zur Therapie mit Cyproteronacetat. In WILLE R, SCHUMACHER W, ANDRZEJAK N (Hg), Zur Therapie von sexuell Devianten (S. 26-42). Berlin: Diesbach
30. LASCHET U, LASCHET L (1967) Antiandrogentherapie der pathologisch gesteigerten und abartigen Sexualität des Mannes. Klinische Wochenschrift 45, 324-325
31. LANGEVIN R, PAITICH D, HUCKER SJ, NEWMAN S, RAMSAY G, POPE S, GELLER G, ANDERSON C (1979) The effect of assertiveness training, Provera, and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry, 10, 275-282
32. LÖSEL F (2001) Evaluating the effectiveness of correctional programs: Bridging the gap between research and practice. In BERNFELD GA, FARRINGTON DP, LESCHIED AW (Eds), Offender Rehabilitation in Practice - Implementing and Evaluating Effective Programs (pp. 67-92). Chichester: Wiley
33. LÖSEL F, SCHMUCKER M (2005) The effectiveness of treatment for sexual offenders: A comprehensive meta-analysis. Journal of Experimental Criminology, 1, 117-146
34. MACKENZIE DL, HICKMAN LJ (1998) What works in corrections? Report to the State of Washington Joint Audit and Review Committee
35. MALETZKY BM (1991) The use of medroxyprogesterone acetate to assist in the treatment of sexual offenders. Annals of Sex Research, 4, 117-129
36. MALETZKY BM, FIELD G (2003) The biological treatment of dangerous sexual offenders. A review and preliminary report of the Oregon pilot depo-Provera program. Aggression and Violent Behavior, 8, 391-412
37. MALETZKY BM, TOLAN A, MCFARLAND B (2006) The Oregon depo-Provera Program: A five-year follow-up. Sexual Abuse, 18, 303-316
38. MARCUS AO, FERNENDEZ MP, DEKEYSER L (1993) Use of gonadotropin releasing hormone analog in treatment of exhibitionism. Clinical Research 41 (1), 107a
39. MCCONAGHY N, BLASZCZYNSKI A, KIDSON W (1988) Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica, 77, 199-206
40. MEYER WJ, COLE C, EMORY E (1992) Depo provera treatment for sex offending behavior: An evaluation of outcome. Bulletin of the American Academy of Psychiatry and the Law, 20, 249-259
41. MONEY J (1986) Lovemaps. Clinical concepts of sexual/erotic health and pathology, paraphilia, and gender transposition in childhood, adolescence, and maturity. New York: Irvington
42. ROSLER A, WITZTUM E (1998) Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. New England Journal of Medicine, 338, 416-422
43. ROUSSEAU L, COUTURE M, DUPONT A, LABRIE F, COUTURE N (1990) Effect of combined androgen blockade with an LHRH agonist and Flutamide in one severe case of male exhibitionism. Canadian Journal Psychiatry 35, 338-341
44. SALEH FM, NIEL T, FISHMAN MJ (2004) Treatment of paraphilia in young adults with leuprolide acetate: A preliminary case report series. Journal Forensic Sciences, 49, 1343-1348
45. SCHMUCKER M (2004) Kann Therapie Rückfälle verhindern? Herbolzheim: Centaurus
46. SCHOBER JM, KUHN PJ, KOVACS PG, EARLE JH, BYRNE PM, FRIES RA (2005) Leuprolide acetate suppresses pedophilic urges and arousability. Archives of Sexual Behavior, 34, 691-705
47. THIBAUT F, CORDIER B, KUHN JM (1993) Effect of a long-lasting gonadotropin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatrica Scandinavica 87, 445-450
48. THIBAUT F, CORDIER B, KUHN J-M (1996) Gonadotropin hormone releasing hormone agonist in cases of severe paraphilia: A lifetime treatment? Psychoneuroendocrinology 21 (4), 411-419
49. WHITE P, BRADLEY C, FERRITER M, HATZIPETROU L (2000) Managements for people with disorders of sexual preference and for convicted sexual offenders. Cochrane Database Syst. Rev., CD000251